NeuroSense Therapeutics
NRSN
17 hedge funds and large institutions have $964K invested in NeuroSense Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
433% more capital invested
Capital invested by funds: $181K → $964K (+$784K)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
55% more funds holding
Funds holding: 11 → 17 (+6)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
1.29% more ownership
Funds ownership: 0.84% → 2.13% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 2 |
Squarepoint
New York
|
+$72.3K |
| 3 |
Morgan Stanley
New York
|
+$42.6K |
| 4 |
Jane Street
New York
|
+$41.6K |
| 5 |
HF
HRT Financial
New York
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$31K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13.7K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$9.95K |
| 4 |
HC
Hurley Capital
New York
|
-$3.16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$956 |
NRSN Hedge Fund Activity: Q2 2025 in Review
17 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2025, worth a combined $964K — up 433% from $181K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NRSN positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $216K. The largest seller was XTX Topco, exiting entirely with an estimated $31K sold.
- 17 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2025, up from 11 in Q1 2025.
- Funds reported $964K of NeuroSense Therapeutics stock for Q2 2025, up 433% quarter-over-quarter.
- 9 funds opened new NeuroSense Therapeutics positions in Q2 2025 and 3 closed out, a net change of +6 holders.
- The largest NeuroSense Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $216K added.
- The largest NeuroSense Therapeutics seller in Q2 2025 was XTX Topco, an estimated $31K sold.
Based on aggregated 13F filings for Q2 2025.